Adding doxycycline to single-dose benzathine penicillin G — the preferred treatment for early syphilis — achieved higher serologic responses in people with HIV than benzathine penicillin G, researchers found.
“Previously, we observed a high rate of chlamydial coinfection among people with HIV. Due to this finding, physicians at our hospital started adding doxycycline 100 mg twice daily for 7 days in combination with benzathine penicillin G (BPG) to treat this coinfection,” Kai-Hsiang Chen, MD, a researcher in the department of internal medicine at National Taiwan University Hospital, told Healio.
“One day, we had the idea, ‘Does doxycycline affect the serologic response of early syphilis?’ This led us to initiate our study,” Chen said.
Chen and colleagues conducted a retrospective study to compare the treatment responses to single-dose BPG combined with 7-day doxycycline vs. BPG alone in people with HIV who also presented with early syphilis.
For the study, which was conducted between January 2018 through March 2022, 223 people with HIV with 307 episodes of early syphilis received single-dose BPG plus doxycycline, while 347 people with HIV accounting for 391 episodes of early syphilis received only BPG.
Overall, the study showed that people with HIV receiving BPG plus doxycycline had a significantly higher serologic response rate at 12 months of treatment than those receiving just BPG (79.5% vs. 70.3%; P = .006).
The study also showed that factors associated with 12-month serologic response included rapid plasma regain titer (adjusted OR = 1.25; 95% CI, 1.15-1.35) and receipt of BPG plus doxycycline (aOR = 1.71; 95% CI, 1.20-2.46).
“Because this is a retrospective study, the findings may be influenced by various factors,” Chen said. “However, it presents an opportunity to enhance serologic outcomes in early syphilis among people with HIV and guides us toward conducting more advanced studies.”
Chen added that the team plans to assess the impact of short-course doxycycline on the development of antimicrobial resistance in further randomized control trials in the future.
By Caitlyn Stulpin
Source: Chen KH, et al. Clin Infect Dis. 2023;doi:10.1093/cid/ciad508.
Source : Healio
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.